X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

0.52 (USD) • At close November 1, 2024
Bedrijfsnaam X4 Pharmaceuticals, Inc.
Symbool XFOR
Munteenheid USD
Prijs 0.519
Beurswaarde 87,451,500
Dividendpercentage 0%
52-weken bereik 0.472 - 1.6
Industrie Biotechnology
Sector Healthcare
CEO Dr. Paula Ragan Ph.D.
Website https://www.x4pharma.com

An error occurred while fetching data.

Over X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical

Vergelijkbare Aandelen

Immunome, Inc. logo

Immunome, Inc.

IMNM

11.59 USD

Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp.

TNXP

0.139 USD

Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc.

CABA

3.71 USD

Nutriband Inc. logo

Nutriband Inc.

NTRB

5.93 USD

Check-Cap Ltd. logo

Check-Cap Ltd.

CHEK

1.15 USD

Delcath Systems, Inc. logo

Delcath Systems, Inc.

DCTH

10.5 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)